- Title
- Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
- Creators
- Alexandra Leary - Institut Gustave RoussyLyndsay Willmott - PhoenixBradley J. Monk - Florida Cancer Specialists & Research InstituteJean-Sébastien FrenelDavid C. Starks - University of Sioux FallsMeena OkeraAngeles Alvarez SecordDavid M. O’Malley - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteLainie Martin - Abramson Cancer CenterKaissa Ouali - Institut Gustave RoussyMartin K. Oehler - Royal Adelaide HospitalJeffrey C. Goh - Queensland University of TechnologyBrian M. Slomovitz - Mount Sinai Medical CenterPeter C. LimCatherine M. ShannonRobert Neff - TriHealthFloor J. Backes - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteDivya RajendranHeekyung ChungDoris KimHailun LiDanielle JandialFiona Simpkins - University of Pennsylvania
- Publication Details
- Molecular cancer therapeutics, Vol.24(10_Supplement), pp.B013-B013
- Identifiers
- 991006230134302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
Molecular cancer therapeutics, Vol.24(10_Supplement), pp.B013-B013
10/22/2025
Metrics
2 Record Views